CN100500157C - 一种含水溶性药物缓释片及制备方法 - Google Patents
一种含水溶性药物缓释片及制备方法 Download PDFInfo
- Publication number
- CN100500157C CN100500157C CN 03140590 CN03140590A CN100500157C CN 100500157 C CN100500157 C CN 100500157C CN 03140590 CN03140590 CN 03140590 CN 03140590 A CN03140590 A CN 03140590A CN 100500157 C CN100500157 C CN 100500157C
- Authority
- CN
- China
- Prior art keywords
- water soluble
- described water
- release tablets
- preparation
- hexadecanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 21
- 239000007939 sustained release tablet Substances 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 12
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 claims description 12
- 229960003827 isosorbide mononitrate Drugs 0.000 claims description 12
- 239000003826 tablet Substances 0.000 claims description 12
- 230000004927 fusion Effects 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 5
- 229960004166 diltiazem Drugs 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- -1 fluidizer Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 3
- 241001062472 Stokellia anisodon Species 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000003086 colorant Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 7
- 239000000470 constituent Substances 0.000 abstract 1
- 230000003578 releasing effect Effects 0.000 description 14
- 238000005516 engineering process Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 6
- 235000019700 dicalcium phosphate Nutrition 0.000 description 6
- 239000001856 Ethyl cellulose Substances 0.000 description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 235000019325 ethyl cellulose Nutrition 0.000 description 5
- 229920001249 ethyl cellulose Polymers 0.000 description 5
- 238000007909 melt granulation Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000013543 active substance Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03140590 CN100500157C (zh) | 2003-06-10 | 2003-06-10 | 一种含水溶性药物缓释片及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03140590 CN100500157C (zh) | 2003-06-10 | 2003-06-10 | 一种含水溶性药物缓释片及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1565426A CN1565426A (zh) | 2005-01-19 |
CN100500157C true CN100500157C (zh) | 2009-06-17 |
Family
ID=34470798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03140590 Expired - Fee Related CN100500157C (zh) | 2003-06-10 | 2003-06-10 | 一种含水溶性药物缓释片及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100500157C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113599387B (zh) * | 2021-09-15 | 2023-03-28 | 山东中医药大学附属医院 | 一种复方制剂及其在制备治疗心绞痛药物中的用途 |
-
2003
- 2003-06-10 CN CN 03140590 patent/CN100500157C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1565426A (zh) | 2005-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0097523B1 (en) | Extended action controlled release compositions | |
EP0301006B1 (en) | Methylprednisolone/sodium carboxymethyl starch tablet composition | |
IL196700A (en) | Pharmaceutical preparation containing {1s– [1a, 2a, 3b (1s *, 2r *), 5b]} - 3 (7 - {[2– (3,4-difluorophenyl) cyclopropyl] amino} –5– (propylthio) - 3h – 1,2,3 – triazolo [4,5 – d] pyrimidin – 3 – yl) –5– (2 – hydroxyethoxy) cyclopentane – 1,2 – diol | |
CN103006649B (zh) | 一种复方制剂缬沙坦氨氯地平片(ⅰ)及其制备方法 | |
CA2721133A1 (en) | Low-dose doxepin formulations and methods of making and using the same | |
CN101288652A (zh) | 一种水溶性药物缓释片剂及其制备方法 | |
CN102908327A (zh) | 伊伐布雷定或其可药用盐的缓释制剂 | |
US5560926A (en) | Process for the production of an S-ibuprofen-containing tablet | |
CN104248767A (zh) | 一种布洛芬制剂及其制备方法 | |
CN102058554A (zh) | 一种以粘合剂雾化状态制粒的缓释片制备方法 | |
WO2015110952A1 (en) | Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof | |
MXPA03009805A (es) | Procedimiento de compactacion para fabricar una forma de dosificacion de fenitoina sodica. | |
CN101791299A (zh) | 一种枸橼酸钾缓释片的制备方法 | |
CN100500157C (zh) | 一种含水溶性药物缓释片及制备方法 | |
EP1906936A2 (en) | Formulations containing losartan and/or its salts | |
CN101507716A (zh) | 硝苯地平缓释制剂及其制备方法 | |
WO2008149201A2 (en) | Stable pharmaceutical composition | |
WO2009043914A1 (en) | Multi particulate matrix system containing galantamine | |
CN103690503B (zh) | 一种双层片的制备方法 | |
US4793999A (en) | Method of manufacturing an antihypertensive, diuretic and antihypokalemic pharmaceutical composition with polyethylene glycol | |
CN110354093A (zh) | 一种枸橼酸莫沙必利药物组合物 | |
US20040058989A1 (en) | Pharmaceutical composition containing citalopram | |
EP2044933A1 (en) | Multi particulate matrix system containing galantamine | |
KR101944085B1 (ko) | 발사르탄 함유 고형 경구제형 및 그 제조방법 | |
CN101537005B (zh) | 可待因和氯苯那敏复方缓释胶囊 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Hainan Shengke Life Scientific Research Institute Assignor: Beijing D-Venturepharm Technology Development Co.,Ltd. Contract fulfillment period: 2009.7.8 to 2017.7.8 Contract record no.: 2009990000743 Denomination of invention: Water-soluble medicine slow release tablet and its preparation method Granted publication date: 20090617 License type: Exclusive license Record date: 20090714 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.7.8 TO 2017.7.8; CHANGE OF CONTRACT Name of requester: HAINAN SHENGKE LIFE SCIENCE RESEARCH INSTITUTE Effective date: 20090714 |
|
ASS | Succession or assignment of patent right |
Owner name: AVENTIS PHARMA (HAINAN) CO., LTD. Free format text: FORMER OWNER: DEZHONG WANQUAN PHARMACEUTICALS TECH. DEV. CO., LTD., BEIJING Effective date: 20110816 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100089 HAIDIAN, BEIJING TO: 570314 HAIKOU, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110816 Address after: 570314 No. 279 Nanhai Road, Haikou Patentee after: AVENTIS PHARMA (HAINAN) Co.,Ltd. Address before: 100089, Wanquan mansion, three Jin Zhuang, Haidian District, Beijing, Sijiqing Patentee before: Beijing D-Venturepharm Technology Development Co.,Ltd. |
|
DD01 | Delivery of document by public notice |
Addressee: Zhai Zhirui Document name: payment instructions |
|
DD01 | Delivery of document by public notice | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090617 |
|
CF01 | Termination of patent right due to non-payment of annual fee |